AgeX Therapeutics Performance
| AGEDelisted Stock | USD 0.74 0.01 1.37% |
The firm shows a Beta (market volatility) of -1.23, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning AgeX Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, AgeX Therapeutics is expected to outperform it. AgeX Therapeutics right now shows a risk of 0.0%. Please confirm AgeX Therapeutics jensen alpha, maximum drawdown, and the relationship between the coefficient of variation and sortino ratio , to decide if AgeX Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days AgeX Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound technical and fundamental indicators, AgeX Therapeutics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 645 K |
AgeX |
AgeX Therapeutics Relative Risk vs. Return Landscape
If you would invest 74.00 in AgeX Therapeutics on August 29, 2024 and sell it today you would earn a total of 0.00 from holding AgeX Therapeutics or generate 0.0% return on investment over 90 days. AgeX Therapeutics is generating negative expected returns assuming volatility of 0.0% on return distribution over 90 days investment horizon. In other words, 0% of stocks are less volatile than AgeX, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
AgeX Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AgeX Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AgeX Therapeutics, and traders can use it to determine the average amount a AgeX Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| AGE |
Based on monthly moving average AgeX Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AgeX Therapeutics by adding AgeX Therapeutics to a well-diversified portfolio.
AgeX Therapeutics Fundamentals Growth
AgeX Stock prices reflect investors' perceptions of the future prospects and financial health of AgeX Therapeutics, and AgeX Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AgeX Stock performance.
| Return On Asset | -0.82 | |||
| Operating Margin | (63.57) % | |||
| Current Valuation | 33.33 M | |||
| Shares Outstanding | 2.5 M | |||
| Price To Earning | (5.95) X | |||
| Price To Book | 12.96 X | |||
| Price To Sales | 221.90 X | |||
| Revenue | 142 K | |||
| EBITDA | (9.83 M) | |||
| Cash And Equivalents | 645 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 4.37 M | |||
| Debt To Equity | 0.75 % | |||
| Book Value Per Share | 5.07 X | |||
| Cash Flow From Operations | (7.8 M) | |||
| Earnings Per Share | (13.36) X | |||
| Total Asset | 11.96 M | |||
| Retained Earnings | (131.01 M) | |||
| Current Asset | 5.06 M | |||
| Current Liabilities | 5.17 M | |||
About AgeX Therapeutics Performance
By analyzing AgeX Therapeutics' fundamental ratios, stakeholders can gain valuable insights into AgeX Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AgeX Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AgeX Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California. Agex Therapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 5 people.Things to note about AgeX Therapeutics performance evaluation
Checking the ongoing alerts about AgeX Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AgeX Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AgeX Therapeutics is now traded under the symbol SER. Please update your portfolios or report it if you believe this is an error. Report It! | |
| AgeX Therapeutics is not yet fully synchronised with the market data | |
| AgeX Therapeutics has some characteristics of a very speculative penny stock | |
| AgeX Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| AgeX Therapeutics has 4.37 M in debt with debt to equity (D/E) ratio of 0.75, which is OK given its current industry classification. AgeX Therapeutics has a current ratio of 0.19, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for AgeX to invest in growth at high rates of return. | |
| The entity reported the last year's revenue of 142 K. Reported Net Loss for the year was (14.8 M) with profit before taxes, overhead, and interest of 125 K. | |
| AgeX Therapeutics has about 645 K in cash with (7.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 76.0% of AgeX Therapeutics shares are held by company insiders |
- Analyzing AgeX Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AgeX Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining AgeX Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AgeX Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of AgeX Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AgeX Therapeutics' stock. These opinions can provide insight into AgeX Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in AgeX Stock
If you are still planning to invest in AgeX Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AgeX Therapeutics' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |